id: marketplace_plan_availability_to_alcohol_consumption_reduction
name: Marketplace Plan Availability â†’ Reduction in Alcohol Consumption Frequency
from_node:
  node_id: marketplace_plan_availability
  node_name: Marketplace Plan Availability
  _original_id: topiramate_availability
to_node:
  node_id: alcohol_consumption_reduction
  node_name: Reduction in Alcohol Consumption Frequency
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Topiramate modulates multiple neurotransmitter systems affected by chronic
  heavy alcohol use including GABA and glutamate pathways'
- 'Step 2: Neurochemical modulation reduces alcohol craving and the reinforcing properties
  of alcohol consumption'
- 'Step 3: Decreased craving and reinforcement lead to reduced frequency of drinking
  episodes'
- 'Step 4: Sustained medication use produces consistent reductions in heavy drinking
  days'
evidence:
  quality_rating: B
  n_studies: 3
  primary_citation: 'Henry R Kranzler and Emily E Hartwell 2023. "Medications for
    treating alcohol use disorder: A narrative review.." *Alcohol, clinical & experimental
    research*. https://doi.org/10.1111/acer.15118'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.669848'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/topiramate_availability_to_alcohol_consumption_reduction.yaml
_category: healthcare_access
